Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan H M Schellens

Showing results (11-20 of 541) with videos related to

Pageof 55
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerJill J J Geenen, Jan H M Schellens
The Oncologist|January 1, 2008
ImatinibChristine E de Kogel, Jan H M Schellens
Trends in Pharmacological Sciences|December 13, 2005
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugsPauline Breedveld, Jos H Beijnen, Jan H M Schellens
Cancer Treatment Reviews|April 17, 2008
Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancerIrma Meijerman, Jos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agentsSuzanne Leijen, Jos H Beijnen, Jan H M Schellens
The Oncologist|August 2, 2006
Herb-drug interactions in oncology: focus on mechanisms of inductionIrma Meijerman, Jos H Beijnen, Jan H M Schellens
The Oncologist|August 7, 2010
BevacizumabFilis Kazazi-Hyseni, Jos H Beijnen, Jan H M Schellens
The Oncologist|June 24, 2006
Symptoms and treatment in cancer therapy-induced early menopauseAnnelies H Boekhout, Jos H Beijnen, Jan H M Schellens
The Oncologist|June 3, 2011
TrastuzumabAnnelies H Boekhout, Jos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Inducing synthetic lethality using PARP inhibitorsDavid S Boss, Jos H Beijnen, Jan H M Schellens
Pageof 55

Showing results (11-20 of 541) with videos related to

Sort By:
Pageof 55
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerJill J J Geenen, Jan H M Schellens
The Oncologist|January 1, 2008
ImatinibChristine E de Kogel, Jan H M Schellens
Trends in Pharmacological Sciences|December 13, 2005
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugsPauline Breedveld, Jos H Beijnen, Jan H M Schellens
Cancer Treatment Reviews|April 17, 2008
Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancerIrma Meijerman, Jos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agentsSuzanne Leijen, Jos H Beijnen, Jan H M Schellens
The Oncologist|August 2, 2006
Herb-drug interactions in oncology: focus on mechanisms of inductionIrma Meijerman, Jos H Beijnen, Jan H M Schellens
The Oncologist|August 7, 2010
BevacizumabFilis Kazazi-Hyseni, Jos H Beijnen, Jan H M Schellens
The Oncologist|June 24, 2006
Symptoms and treatment in cancer therapy-induced early menopauseAnnelies H Boekhout, Jos H Beijnen, Jan H M Schellens
The Oncologist|June 3, 2011
TrastuzumabAnnelies H Boekhout, Jos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Inducing synthetic lethality using PARP inhibitorsDavid S Boss, Jos H Beijnen, Jan H M Schellens
Pageof 55